Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders

Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles

Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126

Protein aggregation and neurodegenerative disease

Ross, C. A., & Poirier, M. A. (2004) · Nature Medicine · doi:10.1038/nm1066 · Cited by 3,454

The blood-brain barrier: Bottleneck in brain drug development

Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798

Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668

Synapse Loss and Microglial Activation Precede Tangles in a P301S Tauopathy Mouse Model

Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.-M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., & Lee, V. M.-Y. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.010 · Cited by 2,208

Tau protein isoforms, phosphorylation and role in neurodegenerative disorders11These authors contributed equally to this work.

Buée, L., Bussière, T., Buée‐Scherrer, V., Delacourte, A., & Hof, P. R. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00019-9 · Cited by 2,142

Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function

SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014

Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model

Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892

Oxidative stress in neurodegeneration: Cause or consequence?

Andersen, J. K. (2004) · Nature Medicine · doi:10.1038/nrn1434 · Cited by 1,869

The distribution of tau in the mammalian central nervous system.

Binder, L. I., Frankfurter, A., & Rebhun, L. I. (1985) · The Journal of cell biology · doi:10.1083/jcb.101.4.1371 · Cited by 1,588

Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein

Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Murphy, M. P., Baker, M., Yu, X., et al. (2000) · Nature Genetics · doi:10.1038/78078 · Cited by 1,371

Axonopathy and Transport Deficits Early in the Pathogenesis of Alzheimer’s Disease

Stokin, G. B., Lillo, C., Falzone, T. L., Brusch, R. G., Rockenstein, E., Mount, S. L., Raman, R., Davies, P., Masliah, E., Williams, D. S., et al. (2005) · Science · doi:10.1126/science.1105681 · Cited by 1,214

GSK-3α regulates production of Alzheimer's disease amyloid-β peptides

Phiel, C. J., Wilson, C., Lee, V. M. ‐., & Klein, P. S. (2003) · Nature · doi:10.1038/nature01640 · Cited by 1,211

Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17.

Hong, M., Zhukareva, V., Vogelsberg-Ragaglia, V., Wszolek, Z., Reed, L., Miller, B., Geschwind, D., Bird, T., McKeel, D., Goate, A., et al. (1998) · Science · doi:10.1126/science.282.5395.1914 · Cited by 1,024

Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease

Oddo, S. (2003) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.08.012 · Cited by 980

Tau is essential to β-amyloid-induced neurotoxicity

Rapoport, M., Dawson, H. N., Binder, L. I., Vitek, M. P., & Ferreira, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092136199 · Cited by 807

O-GlcNAcylation regulates phosphorylation of tau: A mechanism involved in Alzheimer's disease

Liu, F., Iqbal, K., Grundke-Iqbal, I., Hart, G. W., & Gong, C.-X. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400348101 · Cited by 775

Abundant Tau Filaments and Nonapoptotic Neurodegeneration in Transgenic Mice Expressing Human P301S Tau Protein

Allen, B., Ingram, E., Takao, M., Smith, M. J., Jakes, R., Virdee, K., Yoshida, H., Holzer, M., Craxton, M., Emson, P. C., et al. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-21-09340.2002 · Cited by 763

Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs

Forman, M. S., Trojanowski, J. Q., & Lee, V. M.-Y. (2004) · Nature Medicine · doi:10.1038/nm1113 · Cited by 715

Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo

Noble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., Gaynor, K., Wang, L., LaFrancois, J., Feinstein, B., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500466102 · Cited by 709

Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain.

Brandt, R., Léger, J. G., & Lee, G. S. (1995) · The Journal of Cell Biology · doi:10.1083/jcb.131.5.1327 · Cited by 663

The high-affinity HSP90–CHIP complex recognizes and selectively degrades phosphorylated tau client proteins

Dickey, C. A., Kamal, A., Lundgren, K., Klosak, N., Bailey, R. M., Dunmore, J., Ash, P., Shoraka, S., Zlatkovic, J., Eckman, C. B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29715 · Cited by 642

Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer’s disease

Arriagada, P. V., Marzloff, K., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.9.1681 · Cited by 638

Mutations of Tau Protein in Frontotemporal Dementia Promote Aggregation of Paired Helical Filaments by Enhancing Local β-Structure

von Bergen�, M., Barghorn, S., Li, L., Marx, A., Biernat, J., Mandelkow, E., & Mandelkow�, E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105196200 · Cited by 618

Age-Dependent Emergence and Progression of a Tauopathy in Transgenic Mice Overexpressing the Shortest Human Tau Isoform

Ishihara, T., Hong, M., Zhang, B., Nakagawa, Y., Lee, M. K., Trojanowski, J. Q., & Lee, V. M.-Y. (1999) · Neuron · doi:10.1016/s0896-6273(00)81127-7 · Cited by 564

Inhibition of Heparin-induced Tau Filament Formation by Phenothiazines, Polyphenols, and Porphyrins

Taniguchi, S., Suzuki, N., Masuda, M., Hisanaga, S., Iwatsubo, T., Goedert, M., & Hasegawa, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408714200 · Cited by 552

Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines.

Wischik, C. M., Edwards, P. C., Lai, R. Y., Roth, M., & Harrington, C. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.11213 · Cited by 547

The microtubule binding domain of tau protein

Lee, G., Neve, R. L., & Kosik, K. S. (1989) · Neuron · doi:10.1016/0896-6273(89)90050-0 · Cited by 500

Tau filament formation in transgenic mice expressing P301L tau

Götz, J., Chen, F., Barmettler, R., & Nitsch, R. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m006531200 · Cited by 495

Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases

Mazanetz, M. P., & Fischer, P. M. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2111 · Cited by 459

Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo

Fulga, T. A., Elson-Schwab, I., Khurana, V., Steinhilb, M. L., Spires, T. L., Hyman, B. T., & Feany, M. B. (2007) · Nature Cell Biology · doi:10.1038/ncb1528 · Cited by 452

Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice

David, D. C., Hauptmann, S., Scherping, I., Schuessel, K., Keil, U., Rizzu, P., Ravid, R., Dröse, S., Brandt, U., Müller, W. E., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500356200 · Cited by 447

Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform.

Götz, J., Probst, A., Spillantini, M. G., Schäfer, T., Jakes, R., Bürki, K., & Goedert, M. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07116.x · Cited by 441

Alzheimer's Disease-Like Tau Neuropathology Leads to Memory Deficits and Loss of Functional Synapses in a Novel Mutated Tau Transgenic Mouse without Any Motor Deficits

Schindowski, K., Bretteville, A., Leroy, K., Bégard, S., Brion, J., Hamdane, M., & Buée, L. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.060002 · Cited by 438

Mutations causing neurodegenerative tauopathies

Goedert, M., & Jakes, R. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.08.007 · Cited by 438

Post-translational modifications of tau protein in Alzheimer’s disease

Gong, C.-X., Liu, F., Grundke-Iqbal, I., & Iqbal, K. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-004-0221-0 · Cited by 437

Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model

Zhang, B., Maiti, A., Shively, S., Lakhani, F., McDonald-Jones, G., Bruce, J., Lee, E. B., Xie, S. X., Joyce, S., Li, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406361102 · Cited by 413

Presenilin 1 associates with glycogen synthase kinase-3β and its substrate tau

Takashima, A., Murayama, M., Murayama, O., Kohno, T., Honda, T., Yasutake, K., Nihonmatsu, N., Mercken, M. H., Yamaguchi, H., Sugihara, S., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9637 · Cited by 409

Congo red and protein aggregation in neurodegenerative diseases

Frid, P., Anisimov, S. V., & Popović, N. (2006) · Brain Research Reviews · doi:10.1016/j.brainresrev.2006.08.001 · Cited by 405

Prominent Axonopathy in the Brain and Spinal Cord of Transgenic Mice Overexpressing Four-Repeat Human tau Protein

Spittaels, K., den Haute, C. V., Dorpe, J. V., Bruynseels, K., Vandezande, K., Laenen, I., Geerts, H., Mercken, M. H., Sciot, R., Lommel, A. V., et al. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65533-2 · Cited by 390

Axonal transport defects: a common theme in neurodegenerative diseases

Roy, S., Zhang, B., Lee, V. M. ‐., & Trojanowski, J. Q. (2005) · Acta Neuropathologica · doi:10.1007/s00401-004-0952-x · Cited by 384

Temporal Profile of Amyloid-β (Aβ) Oligomerization in an in Vivo Model of Alzheimer Disease

Oddo, S., Caccamo, A., Tran, L., Lambert, M. P., Glabe, C. G., Klein, W. L., & LaFerla, F. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m507892200 · Cited by 379

Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments.

Schweers, O., Mandelkow, E., Biernat, J., & Mandelkow, E. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.18.8463 · Cited by 379

Oxidative Stress and Neurodegeneration

Moreira, P. I., Smith, M. A., Zhu, X., Nunomura, A., Castellani, R. J., & Perry, G. L. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1333.062 · Cited by 370

Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein

Probst, A., Götz, J., Wiederhold, K., Tolnay, M., Mistl, C., Jaton, A., Hong, M., Ishihara, T., Lee, V., Trojanowski, J., et al. (2000) · Acta Neuropathologica · doi:10.1007/s004010051148 · Cited by 362

The Microtubule-associated Protein Tau Is Extensively Modified with O-linked N-acetylglucosamine

Arnold, C. S., Johnson, G. W., Cole, R. N., Dong, D. L.-Y., Lee, M., & Hart, G. W. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.46.28741 · Cited by 361

Repeat motifs of tau bind to the insides of microtubules in the absence of taxol

Kar, S., Fan, J., Smith, M. J., Goedert, M., & Amos, L. A. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg001 · Cited by 355

Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics

Shaw, L. M. J., Korecka, M., Clark, C. M., Lee, V. M. ‐., & Trojanowski, J. Q. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2176 · Cited by 348

Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5

Ahlijanian, M. K., Barrezueta, N. X., Williams, R. D., Jakowski, A. B., Kowsz, K. P., McCarthy, S. A., Coskran, T., Carlo, A. A., Seymour, P. A., Burkhardt, J. E., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040577797 · Cited by 339

Anthraquinones Inhibit Tau Aggregation and Dissolve Alzheimer's Paired Helical Filaments in Vitro and in Cells

Pickhardt, M., Gažová, Z., von Bergen�, M., Khlistunova, I., Wang, Y., Hascher, A., Mandelkow, E., Biernat, J., & Mandelkow�, E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m410984200 · Cited by 334

Promotion of Hyperphosphorylation by Frontotemporal Dementia Tau Mutations

Alonso, A. D. C., Mederlyova, A., Novák, M., Grundke, I., & Iqbal, K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405131200 · Cited by 330

Granular Tau Oligomers as Intermediates of Tau Filaments

Maeda, S., Sahara, N., Saito, Y., Murayama, M., Yoshiike, Y., Kim, H., Miyasaka, T., Murayama, S., Ikai, A., & Takashima, A. (2007) · Biochemistry · doi:10.1021/bi061359o · Cited by 330

Inhibition of protein aggregation in vitro and in vivo by a natural osmoprotectant

Ignatova, Z., & Gierasch, L. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603772103 · Cited by 330

Small Ubiquitin-like Modifier (SUMO) Modification of Natively Unfolded Proteins Tau and α-Synuclein

Dorval, V., & Fraser, P. E. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510127200 · Cited by 319

Alzheimer Disease-specific Conformation of Hyperphosphorylated Paired Helical Filament-Tau Is Polyubiquitinated through Lys-48, Lys-11, and Lys-6 Ubiquitin Conjugation

Cripps, D., Thomas, S. N., Jeng, Y., Yang, F., Davies, P., & Yang, A. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512786200 · Cited by 312

Increased levels of granular tau oligomers: An early sign of brain aging and Alzheimer's disease

Maeda, S., Sahara, N., Saito, Y., Murayama, S., Ikai, A., & Takashima, A. (2006) · Neuroscience Research · doi:10.1016/j.neures.2005.11.009 · Cited by 301

Accelerated filament formation from tau protein with specific FTDP‐17 missense mutations

Nacharaju, P., Lewis, J. M., Easson, C., Yen, S. H., Hackett, J., Hutton, M., & Yen, S.-H. C. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00294-x · Cited by 294

A decade of modeling Alzheimer's disease in transgenic mice

MCGOWAN, E., ERIKSEN, J., & HUTTON, M. (2006) · Trends in Genetics · doi:10.1016/j.tig.2006.03.007 · Cited by 287

Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice

Capsoni, S., Ugolini, G., Comparini, A., Ruberti, F., Berardi, N., & Cattaneo, A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6826 · Cited by 279

Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau

Tatebayashi, Y., Miyasaka, T., Chui, D., Akagi, T., Mishima, K., Iwasaki, K., Fujiwara, M., Tanemura, K., Murayama, M., Ishiguro, K., et al. (2002) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.202205599 · Cited by 279

Characterization of Pathology in Transgenic Mice Over-Expressing Human Genomic and cDNA Tau Transgenes

Duff, K., Knight, H., Refolo, L. M., Sanders, S., Yu, X., Picciano, M., Malester, B., Hutton, M., Adamson, J., Goedert, M., et al. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0279 · Cited by 269

Neurodegeneration with Tau Accumulation in a Transgenic Mouse Expressing V337M Human Tau

Tanemura, K., Murayama, M., Akagi, T., Hashikawa, T., Tominaga, T., Ichikawa, M., Yamaguchi, H., & Takashima, A. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-01-00133.2002 · Cited by 243

Interaction of Tau with the Neural Membrane Cortex Is Regulated by Phosphorylation at Sites That Are Modified in Paired Helical Filaments

Maas, T., Eidenmüller, J., & Brandt, R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000389200 · Cited by 226

Drug discovery in dementia: the role of rodent models

Dam, D. V., & Deyn, P. P. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2075 · Cited by 224

Muscle weakness, hyperactivity, and impairment in fear conditioning in tau-deficient mice

Ikegami, S. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00964-7 · Cited by 221

Therapies for Alzheimer's disease

Melnikova, I. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2314 · Cited by 219

Tau-dependent microtubule disassembly initiated by prefibrillar β-amyloid

King, M. E., Kan, H.-M., Baas, P. W., Erişir, A., Glabe, C. G., & Bloom, G. S. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200605187 · Cited by 215

Quinoline and Benzimidazole Derivatives: Candidate Probes forIn VivoImaging of Tau Pathology in Alzheimer's Disease

Okamura, N., Suemoto, T., Furumoto, S., Suzuki, M., Shimadzu, H., Akatsu, H., Yamamoto, T., Fujiwara, H., Nemoto, M., Maruyama, M., et al. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.1738-05.2005 · Cited by 212

Mutations in tau reduce its microtubule binding properties in intact cells and affect its phosphorylation

Dayanandan, R., van Slegtenhorst, M., Mack, T. G. A., Ko, L., Yen, S. H., Leroy, K., Brion, J., Anderton, B. H., Hutton, M. L., & Lovestone, S. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00222-7 · Cited by 210

FTDP-17 Mutations in tau Transgenic Mice Provoke Lysosomal Abnormalities and Tau Filaments in Forebrain

Lim, F., Hernández, F., Lucas, J. J., Gómez‐Ramos, P., Morán, M. A., & Ávila, J. (2001) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2001.1051 · Cited by 205

Pathways by Which Aβ Facilitates Tau Pathology

Blurton-Jones, M. M., & LaFerla, F. M. (2006) · Current Alzheimer Research · doi:10.2174/156720506779025242 · Cited by 195

Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti‐inflammatory drugs

Townsend, K. P., & Praticò, D. (2005) · The FASEB Journal · doi:10.1096/fj.04-3620rev · Cited by 194

Microtubule structure and its stabilisation

Amos, L. (2004) · Organic & Biomolecular Chemistry · doi:10.1039/b403634d · Cited by 193

SUMO on the road to neurodegeneration

Dorval, V., & Fraser, P. E. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.03.017 · Cited by 188

A Decade of Tau Transgenic Animal Models and Beyond

Götz, J., Deters, N. A., Doldissen, A., Bokhari, L., Ke, Y. D., Wiesner, A., Schönrock, N., & Ittner, L. M. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00051.x · Cited by 179

Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice.

Ishihara, T., Zhang, B., Higuchi, M., Yoshiyama, Y., Trojanowski, J., & Lee, V. (2001) · American Journal of Pathology · doi:10.1016/s0002-9440(10)63997-1 · Cited by 178

Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage

Matsuoka, Y., Gray, A. J., Hirata‐Fukae, C., Minami, S., Waterhouse, E. G., Mattson, M. P., LaFerla, F. M., Gozes, I., & Aisen, P. S. S. (2007) · Journal of Molecular Neuroscience · doi:10.1385/jmn/31:02:165 · Cited by 164

Role of Serine/Threonine Protein Phosphatase in Alzheimer’s Disease

Tian, Q., & Wang, J. (2002) · Neurosignals · doi:10.1159/000067425 · Cited by 156

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Other Anti- Inflammatory Agents in the Treatment of Neurodegenerative Disease

Klegeris, A., & McGeer, P. L. (2005) · Current Alzheimer Research · doi:10.2174/1567205054367883 · Cited by 143

Tau Therapeutic Strategies for the Treatment of Alzheimers Disease

Churcher, I. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606776743057 · Cited by 142

Prominent Axonopathy and Disruption of Axonal Transport in Transgenic Mice Expressing Human Apolipoprotein E4 in Neurons of Brain and Spinal Cord

Tesseur, I. C., Dorpe, J. V., Bruynseels, K., Bronfman, F. C., Sciot, R., Lommel, A. V., & LEUVEN, F. V. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64788-8 · Cited by 140

Pathways of tau fibrillization

Kuret, J., Chirita, C. N., Congdon, E. E., Kannanayakal, T. J., Li, G., Necula, M., Yin, H., & Zhong, Q. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.06.016 · Cited by 135

Transgenic animal models of tauopathies

Lee, V. M. ‐., Kenyon, T. K., & Trojanowski, J. Q. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.06.014 · Cited by 134

Evaluating triggers and enhancers of tau fibrillization

Kuret, J., Congdon, E. E., Li, G., Yin, H., Yu, X., & Zhong, Q. (2005) · Microscopy Research and Technique · doi:10.1002/jemt.20187 · Cited by 119

Concurrent alterations of O‐GlcNAcylation and phosphorylation of tau in mouse brains during fasting

Li, X., Fen, L., Wang, J., & Gong, C. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04735.x · Cited by 116

Tau and src family tyrosine kinases

Lee, G. S. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.09.002 · Cited by 111

Oligodendroglial tau filament formation in transgenic mice expressing G272V tau

Götz, J., Tolnay, M., Barmettler, R., Chen, F., Probst, A., & Nitsch, R. M. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01604.x · Cited by 107

High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation

Crowe, A., Ballatore, C., Hyde, E. G., Trojanowski, J. Q., & Lee, V. M. ‐. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.03.056 · Cited by 105

Ligand-Dependent Inhibition and Reversal of Tau Filament Formation

Chirita, C. N., Necula, M., & Kuret, J. (2004) · Biochemistry · doi:10.1021/bi036094h · Cited by 104

Pathological tau: a loss of normal function or a gain in toxicity?

Trojanowski, J. Q., & Lee, V. M. ‐. (2005) · Nature Neuroscience · doi:10.1038/nn0905-1136 · Cited by 93

Cyanine Dye N744 Inhibits Tau Fibrillization by Blocking Filament Extension: Implications for the Treatment of Tauopathic Neurodegenerative Diseases

Necula, M., Chirita, C. N., & Kuret, J. (2005) · Biochemistry · doi:10.1021/bi050387o · Cited by 91

From epidemiology to therapeutic trials with anti-inflammatory drugs in Alzheimer's disease: The role of NSAIDs and cyclooxygenase in β-amyloidosis and clinical dementia1

Pasinetti, G. M. (2002) · Journal of Alzheimer s Disease · doi:10.3233/jad-2002-4510 · Cited by 89

Assembly of paired helical filaments from mouse tau: implications for the neurofibrillary pathology in transgenic mouse models for Alzheimer's disease

Kampers, T., Pangalos, M. N., Geerts, H., Wiech, H., & Mandelkow, E. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00522-0 · Cited by 86

Novel Method to Quantify Neuropil Threads in Brains from Elders With or Without Cognitive Impairment

Mitchell, T. W., Nissanov, J., Han, L.-Y., Mufson, E. J., Schneider, J. A., Cochran, E. J., Bennett, D. A., Lee, V. M.-Y., Trojanowski, J. Q., & Arnold, S. E. (2000) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215540004801206 · Cited by 78

Screening for Inhibitors of Tau Polymerization

Pickhardt, M., von Bergen�, M., Gažová, Z., Hascher, A., Biernat, J., Mandelkow, E., & Mandelkow�, E. (2005) · Current Alzheimer Research · doi:10.2174/1567205053585891 · Cited by 74

Tau phosphorylation and proteolysis: Insights and perspectives

Johnson, G. V. W. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9s326 · Cited by 69

Microtubule-stabilising drugs for therapy of Alzheimer’s disease and other neurodegenerative disorders with axonal transport impairments

Trojanowski, J. Q., Smith, A. B., Huryn, D. M., & Lee, V. M. ‐. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.5.683 · Cited by 64

Overview of Protein Aggregation in Single, Double, and Triple Neurodegenerative Brain Amyloidoses

Trojanowski, J. Q., & Mattson, M. P. (2003) · NeuroMolecular Medicine · doi:10.1385/nmm:4:1-2:1 · Cited by 53

Glycoxidative stress creates a vicious cycle of neurodegeneration in Alzheimer’s disease — a target for neuroprotective treatment strategies?

Münch, G. W., Deuther‐Conrad, W., & Gasic‐Milenkovic, J. (2002) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6139-5_28 · Cited by 44

Discodermolide interferes with the binding of tau protein to microtubules

Kar, S., Florence, G. J., Paterson, I., & Amos, L. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00181-9 · Cited by 43

Sequence of neurofibrillary changes in aging and Alzheimer's disease: A confocal study with phospho-tau antibody, AD2

Galván, M., David, J., Delacourte, A., Luna, J., & Mena, R. (2001) · Journal of Alzheimer s Disease · doi:10.3233/jad-2001-3409 · Cited by 43

CHIP-ping away at tau

Goryunov, D., & Liem, R. K. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31505 · Cited by 20

How resting T cells deMURR HIV infection

Greene, W. C. (2003) · Nature Immunology · doi:10.1038/ni0104-18 · Cited by 18

Tau modifiers as therapeutic targets for Alzheimer's disease

Liu, Q., Lee, H., Honda, K., Siedlak, S. L., Harris, P. L. R., Cash, A., Zhu, X., Ávila, J., Nunomura, A., Takeda, A., et al. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.06.021 · Cited by 14

Development of a Fluorescent High Throughput Assay for Tau Aggregation

Liu, M., Ni, J., Kosik, K. S., & Yeh, L.-A. (2004) · Assay and Drug Development Technologies · doi:10.1089/adt.2004.2.609 · Cited by 5

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806

Mechanisms underlying inflammation in neurodegeneration

Glass, C. K., Saijo, K., Winner, B., Marchetto, M. C., & Gage, F. H. (2010) · Cell · doi:10.1016/j.cell.2010.02.016 · Cited by 3,580

Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models

Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821

RNA editing with CRISPR-Cas13

Cox, D. B. T., Gootenberg, J. S., Abudayyeh, O. O., Franklin, B., Kellner, M. J., Joung, J., & Zhang, F. (2017) · Science · doi:10.1126/science.aaq0180 · Cited by 1,834

Alzheimer Mechanisms and Therapeutic Strategies

Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758

Connecting the dots between tau dysfunction and neurodegeneration

Frost, B., Götz, J., & Feany, M. B. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.07.005 · Cited by 124

The role of tau in neurodegeneration

Gendron, T. F., & Petrucelli, L. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-13 · Cited by 478

The importance of tau phosphorylation for neurodegenerative diseases

Noble, W., Hanger, D. P., Miller, C. C. J., & Lovestone, S. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00083 · Cited by 475

Phosphorylated Tau in Alzheimer’s Disease and Other Tauopathies

Rawat, P., Sehar, U., Bisht, J., Selman, A., Culberson, J., & Reddy, P. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112841 · Cited by 509

Role of tau protein in Alzheimer’s disease: The prime pathological player

Muralidar, S., Ambi, S. V., Sekaran, S., Thirumalai, D., & Palaniappan, B. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.07.327 · Cited by 278